The activity of LDHA assessed by hyperpolarized-MRSI utilizing 13C-1-pyruvate has been proposed as a biomarker of response to treatment [32] and aggressiveness in gliomas [22]. This evidence concerns the gene LDHA and central nervous system cancer.